DEERFIELD, Ill.--(BUSINESS WIRE)--
Baxter International Inc. (NYSE:BAX) today announced the appointment of
John Orloff, M.D., as vice president and global head of research and
development for Baxter BioScience, effective immediately. Dr. Orloff
joins Baxter from Merck Serono Pharmaceuticals, where he served as
global head of clinical development. Dr. Orloff will be responsible for
advancing the late-stage BioScience pipeline, enhancing the current R&D
operating model and pursuing additional innovative opportunities for the
''As we work toward becoming an independent global biopharmaceutical
company, our priorities are to drive innovation by advancing our rich,
late-stage development pipeline, expanding our expertise in immunology,
hematology, and other core technologies and optimizing our R&D
productivity,'' said Ludwig Hantson, Ph.D., president of Baxter
BioScience. ''John brings significant scientific and leadership
expertise, including preclinical research, clinical development, and
medical and regulatory affairs. He will be a valuable member of our
executive leadership team and a guiding force for effectively executing
the development strategy for our organization.''
Prior to his tenure at Merck Serono, Dr. Orloff spent approximately 10
years at Novartis, where he served in roles of increasing responsibility
including chief medical officer for global development. Earlier in his
career, Dr. Orloff supported clinical development at Merck Research Labs
and was previously a faculty member at the Yale University School of
Medicine. Dr. Orloff’s expertise in bone biology contributed to
marketing approvals for treatments for a range of bone disorders, and he
has led programs across a diverse range of therapeutic areas, including
immunology, neurology and oncology.
Dr. Orloff received an undergraduate degree in chemistry from Dartmouth
College and earned his medical degree from the University of Vermont,
College of Medicine and completed a fellowship in endocrinology and
metabolism at Yale University School of Medicine.
About Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops,
manufactures and markets products that save and sustain the lives of
people with hemophilia, immune disorders, cancer, infectious diseases,
kidney disease, trauma and other chronic and acute medical conditions.
As a global, diversified healthcare company, Baxter applies a unique
combination of expertise in medical devices, pharmaceuticals and
biotechnology to create products that advance patient care worldwide.
Baxter International Inc.
Mary Kay Ladone, 224-948-3371
Source: Baxter International Inc.